Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 6/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4394796 | 0.99 | SMN1; SMN2 (0.57) | SMN1; SMN2RAB9ANPC1TSHRHSD17B10 | |
| SCHEMBL4394505 | 0.93 | RAB9A (0.52) | SMN1; SMN2RAB9ANPC1TSHRHSD17B10 | |
| SCHEMBL4397227 | 0.89 | HDAC3 (0.49) | SMN1; SMN2RAB9ANPC1TSHRHSD17B10 | |
| Hydrochloric Acid SCHEMBL4397221 | 0.89 | HDAC3 (0.48) | SMN1; SMN2RAB9ANPC1TSHRHSD17B10 | |
| SCHEMBL4394714 | 0.88 | LCK (0.47) | SMN1; SMN2RAB9ANPC1TSHRALDH1A1 | |
| SCHEMBL4397038 | 0.87 | ALDH1A1 (0.43) | SMN1; SMN2RAB9ANPC1TSHRHSD17B10 | |
| SCHEMBL4396704 | 0.86 | CLK1 (0.51) | SMN1; SMN2RAB9ANPC1HSD17B10ALDH1A1 | |
| SCHEMBL4396950 | 0.86 | RAB9A (0.47) | SMN1; SMN2RAB9ANPC1TSHRHSD17B10 | |
| Hydrochloric Acid SCHEMBL4397033 | 0.86 | ALDH1A1 (0.42) | SMN1; SMN2RAB9ANPC1TSHRHSD17B10 | |
| Hydrochloric Acid SCHEMBL4397529 | 0.85 | MAPT (0.46) | SMN1; SMN2RAB9ANPC1TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632952-B2 | 4-(2-hydroxy-2-methylpropylamino)benzenesulfonic acid 2-[(piperidine-4-carbonyl)-amino]benzothiazol-6-yl ester; anticancer activity, via modulation of the activity of proteins, in particular of kinases; anticarcinogenic agent | AVENTIS PHARMA S.A. (FR) | 2009-12-15 | — | — | US | claimed |
| US-7632952-B2 | 4-(2-hydroxy-2-methylpropylamino)benzenesulfonic acid 2-[(piperidine-4-carbonyl)-amino]benzothiazol-6-yl ester; anticancer activity, via modulation of the activity of proteins, in particular of kinases; anticarcinogenic agent | AVENTIS PHARMA S.A. (FR) | 2009-12-15 | — | — | US | disclosed |
| US-7632952-B2 | 4-(2-hydroxy-2-methylpropylamino)benzenesulfonic acid 2-[(piperidine-4-carbonyl)-amino]benzothiazol-6-yl ester; anticancer activity, via modulation of the activity of proteins, in particular of kinases; anticarcinogenic agent | AVENTIS PHARMA S.A. (FR) | 2009-12-15 | — | — | US | disclosed |
| US-7632952-B2 | 4-(2-hydroxy-2-methylpropylamino)benzenesulfonic acid 2-[(piperidine-4-carbonyl)-amino]benzothiazol-6-yl ester; anticancer activity, via modulation of the activity of proteins, in particular of kinases; anticarcinogenic agent | AVENTIS PHARMA S.A. (FR) | 2009-12-15 | — | — | US | disclosed |
| US-20070093488-A1 | Novel Benzothiazoles And The Use Thereof As Medicaments | AVENTIS PHARMA S.A. (FR) | 2007-04-26 | — | — | US | disclosed |
| US-20070093488-A1 | Novel Benzothiazoles And The Use Thereof As Medicaments | AVENTIS PHARMA S.A. (FR) | 2007-04-26 | — | — | US | disclosed |
| US-20070093488-A1 | Novel Benzothiazoles And The Use Thereof As Medicaments | AVENTIS PHARMA S.A. (FR) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093488-A1 | Novel Benzothiazoles And The Use Thereof As Medicaments | TFEB, ABAT, BRD4 | SMN1; SMN2 4780/4885RAB9A 4759/4885NPC1 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.